NLS Pharmaceutics AG (NLSP) Analyst Estimates Annual - Discounting Cash Flows
NLSP
NLS Pharmaceutics AG
NLSP (NASDAQ)
Period Ending: 2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
Number of Analysts 1 1 0 0 0
Estimated Revenue
Low 178.6 132.5 0 0 0
Average 178.6 132.5 0 0 0
High 178.6 132.5 0 0 0
Estimated EBITDA
Low 0 0 0 0 0
Average 0 0 0 0 0
High 0 0 0 0 0
Estimated EBIT
Low 0 0 0 0 0
Average 0 0 0 0 0
High 0 0 0 0 0
Estimated Net Income
Low 10.62 6.98 -2.78 -0.247 -580.3
Average 10.62 6.98 -2.78 -0.247 -580.3
High 10.62 6.98 -2.78 -0.247 -580.3
Estimated SGA Expenses
Low 0 0 0 0 0
Average 0 0 0 0 0
High 0 0 0 0 0
Estimated EPS
Low 68.8 45.2 -18 -1.6 -15.2
Average 68.8 45.2 -18 -1.6 -15.2
High 68.8 45.2 -18 -1.6 -15.2
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program